FOLH1 and neoplasm: To (i) identify living tumor cells, (ii) to get an independent metabolic response parameter of the 225Ac-TM-based alpha therapy, and (iii) to show the radiotracer distribution in the tumors, animals of the TAT study (see Figure 6) were additionally imaged with the PSMA targeting compound 18F-JK-PSMA-7.